Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala… Read more
Cyclacel Pharmaceuticals Inc (CYCC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.291x
Based on the latest financial reports, Cyclacel Pharmaceuticals Inc (CYCC) has a cash flow conversion efficiency ratio of -0.291x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.06K) by net assets ($3.63K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cyclacel Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Cyclacel Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cyclacel Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cyclacel Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Posti Group Oyj
HE:POSTI
|
N/A |
|
Pioneer Acquisition I Corp Units
NASDAQ:PACHU
|
N/A |
|
Yulong Eco-Materials Ltd
PINK:YECO
|
0.000x |
|
Nuveen Dynamic Municipal Opportunities Fund
NYSE:NDMO
|
N/A |
|
PPHE Hotel Group Ltd
LSE:PPH
|
0.062x |
|
Evolution Global Acquisition Corp Units
NASDAQ:EVOXU
|
N/A |
|
Baiksan Co. Ltd.
KQ:035150
|
N/A |
|
BSGO39
SA:BSGO39
|
N/A |
Annual Cash Flow Conversion Efficiency for Cyclacel Pharmaceuticals Inc (2003–2024)
The table below shows the annual cash flow conversion efficiency of Cyclacel Pharmaceuticals Inc from 2003 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-2.17 Million | $-7.99 Million | 3.675x | +113.85% |
| 2023-12-31 | $607.00K | $-16.11 Million | -26.544x | -2504.15% |
| 2022-12-31 | $20.43 Million | $-20.83 Million | -1.019x | -107.23% |
| 2021-12-31 | $37.69 Million | $-18.54 Million | -0.492x | -106.19% |
| 2020-12-31 | $33.26 Million | $-7.93 Million | -0.239x | +70.46% |
| 2019-12-31 | $11.70 Million | $-9.45 Million | -0.808x | -84.07% |
| 2018-12-31 | $15.27 Million | $-6.70 Million | -0.439x | -27.68% |
| 2017-12-31 | $21.77 Million | $-7.48 Million | -0.344x | +51.33% |
| 2016-12-31 | $14.27 Million | $-10.08 Million | -0.706x | +8.02% |
| 2015-12-31 | $18.84 Million | $-14.46 Million | -0.768x | +10.97% |
| 2014-12-31 | $21.69 Million | $-18.70 Million | -0.862x | -32.78% |
| 2013-12-31 | $28.02 Million | $-18.20 Million | -0.649x | +45.97% |
| 2012-12-31 | $10.02 Million | $-12.04 Million | -1.202x | -67.70% |
| 2011-12-31 | $19.50 Million | $-13.98 Million | -0.717x | -11.35% |
| 2010-12-31 | $24.92 Million | $-16.04 Million | -0.644x | +80.32% |
| 2009-12-31 | $4.64 Million | $-15.19 Million | -3.272x | -125.82% |
| 2008-12-31 | $20.64 Million | $-29.91 Million | -1.449x | -262.93% |
| 2007-12-31 | $57.97 Million | $-23.14 Million | -0.399x | -6.70% |
| 2006-12-31 | $53.92 Million | $-20.17 Million | -0.374x | +74.60% |
| 2005-12-31 | $14.60 Million | $-21.51 Million | -1.473x | -208.20% |
| 2004-12-31 | $44.12 Million | $-21.09 Million | -0.478x | -300.11% |
| 2003-12-31 | $-64.84 Million | $-15.49 Million | 0.239x | -- |